The results of early clinical studies in newly diagnosed or relapsed/refractory FLT3-mutated AML patients using second-generation FLT3 inhibitors like gilteritinib in combination with other agents are encouraging, and if confirmed in larger studies, may further improve the outcome of this patient population [23]. Here, FLT3 is linked to acute myeloid leukemia.